SCHEMBL5469847

SCHEMBL5469847

O=C1Nc2ccc(C(F)(F)F)cc2/C1=C\c1c[nH]c2ccccc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 7/20 0.68
RET P07949 3/20 0.68
KDR P35968 3/20 0.68
NTRK3 Q16288 3/20 0.68
NTRK2 Q16620 3/20 0.68
FLT3 P36888 3/20 0.68
PRKD3 O94806 2/20 0.68
ABL1 P00519 2/20 0.68
PDGFRB P09619 2/20 0.68
LTK P29376 2/20 0.68
CSNK1A1 P48729 2/20 0.68
CDK7 P50613 2/20 0.68
MAP2K1 Q02750 2/20 0.68
MST1R Q04912 2/20 0.68
AURKB Q96GD4 2/20 0.68
CLK4 Q9HAZ1 2/20 0.68
ALK Q9UM73 2/20 0.68
DAPK3 O43293 1/20 0.68
MAP4K4 O95819 1/20 0.68
LCK P06239 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5469851 1.00 NTRK1 (0.68) NTRK1RETKDRNTRK3NTRK2
SCHEMBL5473205 0.91 NTRK1 (0.68) NTRK1RETKDRNTRK3NTRK2
SCHEMBL5473204 0.91 NTRK1 (0.68) NTRK1RETKDRNTRK3NTRK2
SCHEMBL14448945 0.91 NTRK1 (0.68) NTRK1RETKDRNTRK3NTRK2
SCHEMBL5358796 0.84 NTRK1 (0.65) NTRK1RETKDRNTRK3NTRK2
SCHEMBL14448917 0.82 LRRK2 (0.73) NTRK1RETKDRNTRK3NTRK2
SCHEMBL5464546 0.82 LRRK2 (0.73) NTRK1RETKDRNTRK3NTRK2
SCHEMBL5470630 0.82 NTRK1 (0.73) NTRK1RETKDRNTRK3NTRK2
SCHEMBL5472578 0.82 NTRK1 (0.73) NTRK1RETKDRNTRK3NTRK2
SCHEMBL5472580 0.82 NTRK1 (0.73) NTRK1RETKDRNTRK3NTRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US claimed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO claimed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 NTRK1 175/4885RET 3720/4885KDR 4334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.